#Merck beats 2Q profit forecasts. Read more: https://t.co/KSGNt4XfWG $MRK
#Merck's Profit And Revenue Rise Above Expectations. Read more: https://t.co/icKRMrIQ0A $MRK
#Merck beats 2Q profit forecasts. Read more: https://t.co/P8CRtYgjNz $MRK
RT @Merck: A closing word from Ken Frazier on our 2Q financial results. $MRK https://t.co/xMP2qd0uii
RT MarketCurrents: Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance https://t.co/anXBkV04YY #premarket $MRK,#love
#Merck beats 2Q profit forecasts. Read more: https://t.co/BX3J2HXIy1 $MRK
#Merck beats 2Q profit forecasts. Read more: https://t.co/wkDAlPLq8c $MRK
#Merck's 2Q Earnings Beat Expectations. Read more: https://t.co/qjpZtmhqiw $MRK
RT @Merck: A closing word from Ken Frazier on our 2Q financial results. $MRK https://t.co/xMP2qd0uii
#Merck & Co Inc. Reveals 6% Rise In Q2 Bottom Line. Read more: https://t.co/Pvz9jtYXXX $MRK
RT @Merck: Check out the highlights from this morning’s financial results. $MRK https://t.co/cO46uJeXzz
#Merck beats 2Q profit forecasts. Read more: https://t.co/LCE8kkKOO1 $MRK
RT @Merck: “We continue to have a number of opportunities in our pipeline w/ new product launches & potential for business development.” -R…
RT @Merck: “We're engaging in scientific & commercial partnerships to pair our best internal inventions w/ the best external innovation.” -…
RT @Merck: “We are committed to finding the best external science to enrich our pipeline and portfolio.” -Ken Frazier $MRK
Bidding war possible for an undervalued health care stock: https://t.co/zV6Y5LrffO $MRK $CLNE $GIS $HES $SVU $CDE $QSR $RHT $TCAP
#Merck beats 2Q profit forecasts, lowers guidance. Read more: https://t.co/3BoAwfPnqw $MRK
#Merck beats 2Q profit forecasts. Read more: https://t.co/gRT4n5vrUk $MRK
Morning Call For July 29, 2016 $CI $MRK $NEE $PEG $TYC $UPS $VTR $XRX $STMP $AMZN $EXPE $GOOG $WYNN $PSX https://t.co/zZ84tVhoxj
#Merck beats 2Q profit forecasts, lowers guidance. Read more: https://t.co/sNDHEh1Qno $MRK
RT @YahooFinance: #Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
#Merck beats 2Q profit forecasts. Read more: https://t.co/Mbo6bDKEeK $MRK
#Merck beats 2Q profit forecasts. Read more: https://t.co/eQ6tWBT3H4 $MRK
#Merck beats 2Q profit forecasts. Read more: https://t.co/LiKadmgAL3 $MRK
$MRK I told you to sell off some of your merck holdings.if you did you could be saving a lot of $ like I am. the REAL nobear
$MRK active, relative volume: 10.56, 1H, 9:00 AM, #nyse $DJI $SPY
Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance https://t.co/B3V6B2qvOz #premarket $MRK
Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance https://t.co/J8oqA3a6RB #premarket $MRK
Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance https://t.co/L3uljD2ONX #premarket $MRK
$MRK: Merck announces that the EC has approved ZEPATIER with or without ribavirin for the treatment of chronic... https://t.co/TGCFK9erQn
RT @fezziwig2008: #Keytruda 22% ORR in Gastric Ca $HALO Up'd Abraxane> 23% to 55% in harder to Rx PDA- Awaiting AA in Q4 $MRK $CELG https:/…
OpenOutcrier: $MRK (+1.1% pre) Merck posts better-than-expected quarterly profit, revenue - Reuters
https://t.co/5nFDAUVxru
RT @YahooFinance: #Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
A closing word from Ken Frazier on our 2Q financial results. $MRK https://t.co/xMP2qd0uii
RT @WhisperNumber: This mornings earnings results $CVX, $UPS, $MRK, $CI, $XOM, $NWL big misses by CVX and XOM https://t.co/CcnkIbe8S1
This mornings earnings results $CVX, $UPS, $MRK, $CI, $XOM, $NWL big misses by CVX and XOM https://t.co/CcnkIbe8S1
RT @OpenOutcrier: $MRK (+1.1% pre) Merck posts better-than-expected quarterly profit, revenue - Reuters
https://t.co/9wSwqzskZs
$MRK (+1.1% pre) Merck posts better-than-expected quarterly profit, revenue - Reuters
https://t.co/9wSwqzskZs
$MRK EPS 93c vs 92c est https://t.co/YTZcIhthrW
$MRK: Merck beats by $0.02, reports revs in-line; guides FY16 EPS in-line, revs in-line https://t.co/npslJUsXbX
Merck & Co. updates FY16 guidance to $3.67-3.77 EPS & revenue guidance to $39.1-40.1 billion. https://t.co/6gO7hALvQx $MRK #MRK
$MRK #Options OI chart. Free stock station app https://t.co/cnRpv1ZINg #iTunes https://t.co/e77WAT9Rne
RT @YahooFinance: #Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
RT @BioStocks: $MRK European Commission Grants Marketing Authorisation For ZEPATIER
#Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/6R4oZ9sZDh https://t.co/j1r8Kezh1s YahooFinance RT
EARLY MORNING MOVERS: $MRK $GE $EXE $XRX $GOOG $GOOL $AAPL $FB $CI $AN $LXK $NWL $CBS $WYNN $DECK $WDC $MSFT - CNBC https://t.co/2eUGa8XAvD
EARLY MORNING MOVERS: $MRK $GE $EXE $XRX $GOOG $GOOL $AAPL $FB $CI $AN $LXK $NWL $CBS $WYNN $DECK $WDC $MSFT - CNBC https://t.co/dfXztHqjcE
RT @bradloncar: Here is an updated chart comparing the Opdivo and Keytruda launches. $BMY $MRK https://t.co/uz2ySHFdHS
RT @YahooFinance: #Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
Merck $MRK Reports Q2 Adj. EPS $0.93 vs $0.91 Est., Sales $9.844B vs $9.78B Est #stocks #trading #trade #Earnings $DJIA $DIA $QQQ $SPY
RT @fwpharma: Merck & Co. posts increase in Q2 profit, as cancer, hepatitis C drugs lead sales rise https://t.co/yyVZrYzbrU $MRK #pharma
#Merck beats 2Q profit forecasts, lowers guidance. Read more: https://t.co/dvXoQvAKFq $MRK
RT @bradloncar: Here is an updated chart comparing the Opdivo and Keytruda launches. $BMY $MRK https://t.co/uz2ySHFdHS
RT @jonnajarian: $MRK Q2 $0.93 versus $0.92 est on inline revenue - Also raised guidance for full year, shares $59.43 https://t.co/fdizIyU…
RT @YahooFinance: #Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
RT @TylerHCanalyst: 2Q #HCV
$GILD $3.92B
$BMY $546M
$ABBV $419M
$MRK $112M
$JNJ $43M
RT @fwpharma: Merck & Co. posts increase in Q2 profit, as cancer, hepatitis C drugs lead sales rise https://t.co/yyVZrYzbrU $MRK #pharma
RT @Benzinga: 12 Stocks You Should Be Watching Today $AMZN $CI $CVX $UPS $GOOGL $PSX $MRK $EXPE $XOM $WDC $WYNN $HST https://t.co/RBQQEoio4Y
RT @FredrikRydlun: Can an Apple a day chase overbought away?https://t.co/UqvqnPQfag $AAPL $BA $CAT $CSCO $CVX $DIS $GE $GS $IBM $JPM $KO $M…
#Stocks to Watch Today: $XOM, $UPS, $MRK, $AMZN, $GOOGL https://t.co/zu7UkIXesm https://t.co/5fPuq2clFU
Merck & Co. posts increase in Q2 profit, as cancer, hepatitis C drugs lead sales rise https://t.co/yyVZrYzbrU $MRK #pharma
Early movers: $MRK $GE $EXE $XRX $GOOGL
$AAPL $FB $ &CI $EXPE $SAVE $AMZN $CBS
$WYNN $WDC $MSFT more https://t.co/WXqOtoPOMB
#Merck : Announces Second-Quarter 2016 Financial Results. Read more: https://t.co/Q7mcYzfiic $MRK
$MRK:
Merck Raises EPS Outlook After Q2 Earnings:
https://t.co/ahR75tkXrt
RT @EquityClock: Seasonal charts of companies reporting earnings today: https://t.co/SjwKzFNmLq $ABEV $BUD $AN $BCS $COG $CVX $XOM $IMO $MR…
$MRK keeps saying "Everyone will get tested in 1L lung"
so it isn't going to matter if $BMY gets "all comers" ... well ok
Notable #Earnings 2016.07.29
$ABBV $AN $BCS $BUD $COG $CI $CVX $MRK $PSX $SAVE $SNE $UPS $XOM $XRX
“We're continuing to explore additional treatments for the 150 million+ people w/ hep C virus infection around the world.”-R.Perlmutter $MRK
#Merck and AmoyDx to jointly introduce liquid biopsy RAS biomarker test in China
... Read more: https://t.co/rdPaYmlN7F $MRK
#Merck signs pact with AmoyDx to develop and commercialise new liquid biopsy RAS biomarker t... Read more: https://t.co/7E6lBknYTI $MRK
RT @Merck: “We are committed to finding the best external science to enrich our pipeline and portfolio.” -Ken Frazier $MRK
#Update Early movers: $MRK $GE $EXE $XRX $GOOGL $AAPL $FB
Benzinga: Investors Greet Merck Q2 Results As Key Launches Help Beat $MRK https://t.co/8N99xoizvH
RT @Merck: “We continue to have a number of opportunities in our pipeline w/ new product launches & potential for business development.” -R…
RT @Merck: “We remain confident in our diabetes franchise and are pleased with our continued strong access expected in 2017.” –@AdamHSchech…
RT @Merck: “We have momentum in our core focus areas and strong execution for our key launches." -@AdamHSchechter $MRK
RT @Merck: “We made significant progress in gaining registration for important new products and advanced a number of new programs.” -R. Per…
RT @Loftus: Second-quarter sales of anti-PD-1 cancer immunotherapies:
Bristol's Opdivo: $840 million
Merck's Keytruda: $314 million
$BMY $M…
“We made significant progress in gaining registration for important new products and advanced a number of new programs.” -R. Perlmutter $MRK
RT @Merck: Check out the highlights from this morning’s financial results. $MRK https://t.co/cO46uJeXzz
RT @Merck: “We remain confident in our diabetes franchise and are pleased with our continued strong access expected in 2017.” –@AdamHSchech…
RT @Merck: “We remain confident in our diabetes franchise and are pleased with our continued strong access expected in 2017.” –@AdamHSchech…
Second-quarter sales of anti-PD-1 cancer immunotherapies:
Bristol's Opdivo: $840 million
Merck's Keytruda: $314 million
$BMY $MRK
“We have momentum in our core focus areas and strong execution for our key launches." -@AdamHSchechter $MRK
Benzinga: Investors Greet Merck Q2 Results As Key Launches Help Beat $MRK https://t.co/UvK77r7Oym
RT @Merck: “We are committed to finding the best external science to enrich our pipeline and portfolio.” -Ken Frazier $MRK
RT @Merck: “We're engaging in scientific & commercial partnerships to pair our best internal inventions w/ the best external innovation.” -…
@ohadhammer Unfortunately I haven’t seen that specifically, though I believe $MRK’s numbers are still almost entirely melanoma.
$MRK active, relative volume: 14.44, 1H, 8:00 AM, #nyse $DJI $SPY
RT @bradloncar: Here is an updated chart comparing the Opdivo and Keytruda launches. $BMY $MRK https://t.co/uz2ySHFdHS
Merck $MRK share prices up slightly in pre-market trading on earnings beat. Sitting at $58.99 per share right now.
“We remain confident in our diabetes franchise and are pleased with our continued strong access expected in 2017.” –@AdamHSchechter $MRK
RT @TylerHCanalyst: 2Q #HCV
$GILD $3.92B
$BMY $546M
$ABBV $419M
$MRK $112M
$JNJ $43M
“We continue to have a number of opportunities in our pipeline w/ new product launches & potential for business development.” -R. Davis $MRK
Merck $MRK beats consensus by 2 cents, raking in 93 cents EPS. Revenues were $9.8 billion vs. consensus estimates of $9.7 billion.
$MRK beat on #EPS & #revenue, & raised full year guidance. Good news for $INCY and the #epacadostat & #Keytruda collaboration
Interesting comparison of drug launches for $MRK and $BMY. Covering Merck earnings this morning. https://t.co/HQEgJQ7l76
RT @Merck: “We're engaging in scientific & commercial partnerships to pair our best internal inventions w/ the best external innovation.” -…